These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35274753)

  • 1. The utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia.
    Januszewicz W; Pilonis ND; Sawas T; Phillips R; O'Donovan M; Miremadi A; Malhotra S; Tripathi M; Blasko A; Katzka DA; Fitzgerald RC; di Pietro M
    Histopathology; 2022 Jun; 80(7):1081-1090. PubMed ID: 35274753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia.
    Chen X; Liu BL; Harpaz N; Zhu H; Polydorides AD; Liu Q
    Histopathology; 2023 Feb; 82(3):454-465. PubMed ID: 36251540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved diagnostic stratification of digitised Barrett's oesophagus biopsies by p53 immunohistochemical staining.
    van der Wel MJ; Duits LC; Pouw RE; Seldenrijk CA; Offerhaus GJA; Visser M; Ten Kate FJ; Biermann K; Brosens LAA; Doukas M; Huysentruyt C; Karrenbeld A; Kats-Ugurlu G; van der Laan JS; van Lijnschoten GI; Moll FCP; Ooms AHAG; van der Valk H; Tijssen JG; Bergman JJ; Meijer SL
    Histopathology; 2018 May; 72(6):1015-1023. PubMed ID: 29314176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of p53 immunohistochemistry in conjunction with routine histology improves risk stratification of patients with Barrett's oesophagus during routine clinical care.
    Tokuyama M; Geisler D; Deitrick C; Fasanella KE; Chennat JS; McGrath KM; Pai RK; Davison JM
    Histopathology; 2020 Sep; 77(3):481-491. PubMed ID: 32431062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproducible.
    Kaye PV; Ilyas M; Soomro I; Haider SA; Atwal G; Menon S; Gill S; Richards C; Harrison R; West K; Ragunath K
    Histopathology; 2016 Sep; 69(3):431-40. PubMed ID: 26918780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
    Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
    Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
    Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
    Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathologist features predictive of diagnostic concordance at expert level among a large international sample of pathologists diagnosing Barrett's dysplasia using digital pathology.
    van der Wel MJ; Coleman HG; Bergman JJGHM; Jansen M; Meijer SL;
    Gut; 2020 May; 69(5):811-822. PubMed ID: 31852770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists.
    Kerkhof M; van Dekken H; Steyerberg EW; Meijer GA; Mulder AH; de Bruïne A; Driessen A; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD;
    Histopathology; 2007 Jun; 50(7):920-7. PubMed ID: 17543082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus.
    van Sandick JW; Baak JP; van Lanschot JJ; Polkowski W; ten Kate FJ; Obertop H; Offerhaus GJ
    J Pathol; 2000 Feb; 190(2):177-83. PubMed ID: 10657016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the updated confocal laser endomicroscopy criteria for Barrett's esophagus among gastrointestinal pathologists.
    Tofteland N; Singh M; Gaddam S; Wani SB; Gupta N; Rastogi A; Bansal A; Kanakadandi V; McGregor DH; Ulusarac O; Cherian R; Mathur SC; Sharma P
    Dis Esophagus; 2014; 27(7):623-9. PubMed ID: 24006939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry.
    Kaye PV; Haider SA; Ilyas M; James PD; Soomro I; Faisal W; Catton J; Parsons SL; Ragunath K
    Histopathology; 2009 May; 54(6):699-712. PubMed ID: 19438745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.
    Huhta H; Melkko J; Kuopio T; Karttunen TJ; Helminen O
    Scand J Gastroenterol; 2022 Sep; 57(9):1024-1029. PubMed ID: 35450519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase).
    Sonwalkar SA; Rotimi O; Scott N; Verghese E; Dixon M; Axon AT; Everett SM
    Histopathology; 2010 Jun; 56(7):900-7. PubMed ID: 20636793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
    Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
    Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia.
    Henn AJ; Song KY; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32399569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.